港股异动丨堃博医疗-B涨近10%，BroncTarget进入创新医疗器械特别审查通道

Core Viewpoint - KPB Medical-B (2216.HK) shares rose nearly 10% to HKD 2.65, with a total market capitalization of HKD 1.395 billion, following the announcement that its BroncTarget® lung-targeted radiofrequency ablation system has entered the special review process by the National Medical Products Administration of China, indicating recognition of its original technology and clinical value [1] Company Summary - KPB Medical-B's BroncTarget® system is a breakthrough interventional technology aimed at treating moderate to severe chronic obstructive pulmonary disease (COPD), focusing on alleviating symptoms such as cough, sputum production, and breathing difficulties [1] - The confirmatory clinical trials for the BroncTarget® system are currently underway, with participant recruitment being conducted across 28 hospitals nationwide [1] Market Performance - The stock price of KPB Medical-B reached a high of HKD 2.70 and opened at HKD 2.50, with a trading volume of 1.271 million shares [1] - The stock experienced a price fluctuation of 11.20% and has a total share capital of 527 million [1]